|
1
|
Boffa MB, Maret D, Hamill JD, Bastajian N,
Crainich P, Jenny NS, Tang Z, Macy EM, Tracy RP, Franco RF, et al:
Effect of single nucleotide polymorphisms on expression of the gene
encoding thrombin-activatable fibrinolysis inhibitor: A functional
analysis. Blood. 111:183–189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bajzar L: Thrombin activatable
fibrinolysis inhibitor and an antifibrinolytic pathway.
Arterioscler Thromb Vasc Biol. 20:2511–2518. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Redlitz A, Tan AK, Eaton DL and Plow EF:
Plasma carboxypeptidases as regulators of theplasminogen system. J
Clin Invest. 96:2534–2538. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang W, Boffa MB, Bajzar L, Walker JB and
Nesheim ME: A study of the mechanism of inhibition of fibrinolysis
by activated thrombin-activable fibrinolysis inhibitor. J Biol
Chem. 273:27176–27181. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boffa MB, Hamill JD, Bastajian N, Dillon
R, Nesheim ME and Koschinsky ML: A role for CCAAT/enhancer-binding
protein in hepatic expression of thrombin-activable fibrinolysis
inhibitor. J Biol Chem. 277:25329–25336. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pereira PJ Barbosa, Segura-Martin S, Oliva
B, Ferrer-Orta C, Avilés FX, Coll M, Gomis-Rüth FX and Vendrell J:
Human procarboxypeptidase B: Three-dimensional structure and
implications for thrombin-activatable fibrinolysis inhibitor
(TAFI). J Mol Biol. 321:537–547. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hosaka Y, Takahashi Y and Ishii H:
Thrombomodulin in human plasma contributes to inhibit fibrinolysis
through acceleration of thrombin-dependent activation of plasma
procarboxypeptidase B. Thromb Haemost. 79:371–377. 1998.PubMed/NCBI
|
|
8
|
Tamura A, Hebisawa A, Hayashi K, Sagara Y,
Fukushima K, Kurashima A, Yotsumoto H, Mori M and Komatsu H:
Prognostic significance of thrombomodulin expression and vascular
invasion in stage I squamous cell carcinoma of the lung. Lung
Cancer. 34:375–382. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reijerkerk A, Meijers JC, Havik SR, Bouma
BN, Voest EE and Gebbink MF: Tumor growth and metastasis are not
affected in thrombin-activatable fibrinolysis inhibitor-deficient
mice. J Thromb Haemost. 2:769–779. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fawzy MS, Mohammed EA, Ahmed AS and
Fakhr-Eldeen A: Thrombin-activatable fibrinolysis inhibitor
Thr325Ile polymorphism and plasma level in breast cancer: A pilot
study. Meta Gene. 4:73–84. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fawzy MS and Toraih EA: Data supporting
the structural and functional characterization of
Thrombin-Activatable Fibrinolysis Inhibitor in breast cancer. Data
Brief. 5:981–989. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yeung TL, Leung CS, Wong KK, Samimi G,
Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ and Mok SC: TGF-β
modulates ovarian cancer invasion by upregulating CAF-derived
versican in the tumor microenvironment. Cancer Res. 73:5016–5028.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miller TW, Balko JM, Fox EM, Ghazoui Z,
Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, et
al: ERα-dependent E2F transcription can mediate resistance to
estrogen deprivation in human breast cancer. Cancer Discov.
1:338–351. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hataji O, Taguchi O, Gabazza EC, Yuda H,
D'Alessandro-Gabazza CN, Fujimoto H, Nishii Y, Hayashi T, Suzuki K
and Adachi Y: Increased circulating levels of thrombin-activatable
fibrinolysis inhibitor in lung cancer patients. Am J Hematol.
76:214–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fidan E, Kavgaci H, Orem A, Yilmaz M,
Yildiz B, Fidan S, Akcan B, Ozdemir F and Aydin F: Thrombin
activatable fibrinolysis inhibitor and
thrombin-antithrombin-III-complex levels in patients with gastric
cancer. Tumour Biol. 33:1519–1525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang Z, Miao X, Luan Y, Zhu L, Kong F, Lu
Q, Pernow J, Nilsson G and Li N: PAR1-stimulated platelet releasate
promotes angiogenic activities of endothelial progenitor cells more
potently than PAR4-stimulated platelet releasate. J Thromb Haemost.
13:465–476. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cui J, Hollmén M, Li L, Chen Y, Proulx ST,
Reker D, Schneider G and Detmar M: New use of an old drug:
Inhibition of breast cancer stem cells by benztropine mesylate.
Oncotarget. 8:1007–1022. 2017.PubMed/NCBI
|
|
18
|
Chung SS and Vadgama JV: Curcumin and
epigallocatechin gallate inhibit the cancer stem cell phenotype via
down-regulation of STAT3-NFκB signaling. Anticancer Res. 35:39–46.
2015.PubMed/NCBI
|
|
19
|
Ramachandran C and You W: Differential
sensitivity of human mammary epithelial and breast carcinoma cell
lines to curcumin. Breast Cancer Res Treat. 54:269–278. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu X, Jiang L, Li Q and Gu Y: Quantitative
assessment of background parenchymal enhancement in breast magnetic
resonance images predicts the risk of breast cancer. Oncotarget.
8:10620–10627. 2017.PubMed/NCBI
|
|
21
|
Zhang F, Zhang Y, Deng Z, Xu P, Zhang X,
Jin T and Liu Q: Genetic variants in the acylphosphatase 2 gene and
the risk of breast cancer in a Han Chinese population. Oncotarget.
7:86704–86712. 2016.PubMed/NCBI
|
|
22
|
Kvolik S, Jukic M, Matijevic M, Marjanovic
K and Glavas-Obrovac L: An overview of coagulation disorders in
cancer patients. Surg Oncol. 19:e33–e46. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
De Cicco M: The prothrombotic state in
cancer: Pathogenic mechanisms. Crit Rev Oncol Hematol. 50:187–196.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mosnier LO and Bouma BN: Regulation of
fibrinolysis by thrombin activatable fibrinolysis inhibitor, an
unstable carboxypeptidase B that unites the pathways of coagulation
and fibrinolysis. Arterioscler Thromb Vasc Biol. 26:2445–2453.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Antovic JP and Blombäck M:
Thrombin-activatable fibrinolysis inhibitor antigen and TAFI
activity in patients with APC resistance caused by factor V Leiden
mutation. Thromb Res. 106:59–62. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miah MF and Boffa MB: Functional analysis
of mutant variants of thrombin-activatable fibrinolysis inhibitor
resistant to activation by thrombin or plasmin. J Thromb Haemost.
7:665–672. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nesheim M: Thrombin and fibrinolysis.
Chest. 124:(Suppl 3). 33S–39S. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boffa MB and Koschinsky ML: Curiouser and
curiouser: Recent advances in measurement of thrombin-activatable
fibrinolysis inhibitor (TAFI) and in understanding its molecular
genetics, gene regulation, and biological roles. Clin Biochem.
40:431–442. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chengwei X, Xiaoli M, Yuan Z, Li P,
Shengjiang W, Chao Y and Yunshan W: Plasma thrombin-activatable
fibrinolysis inhibitor levels and its Thr325Ile polymorphism in
breast cancer. Blood Coagul Fibrinolysis. 24:698–703. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Balcik OS, Albayrak M, Uyar ME, Dagdas S,
Yokus O, Ceran F, Cipil H, Kosar A and Ozet G: Serum thrombin
activatable fibrinolysis inhibitor levels in patients with newly
diagnosed multiple myeloma. Blood Coagul Fibrinolysis. 22:260–263.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Higuchi T, Nakamura T, Kakutani H and
Ishii H: Thrombomodulin suppresses invasiveness of HT1080 tumor
cells by reducing plasminogen activation on the cell surface
through activation of thrombin-activatable fibrinolysis inhibitor.
Biol Pharm Bull. 32:179–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luo J, Lee S Ok, Liang L, Huang CK, Li L,
Wen S and Chang C: Infiltrating bone marrow mesenchymal stem cells
increase prostate cancer stem cell population and metastatic
ability via secreting cytokines to suppress androgen receptor
signaling. Oncogene. 33:2768–2778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Eichbaum C, Meyer AS, Wang N, Bischofs E,
Steinborn A, Bruckner T, Brodt P, Sohn C and Eichbaum MH: Breast
cancer cell-derived cytokines, macrophages and cell adhesion:
Implications for metastasis. Anticancer Res. 31:3219–3227.
2011.PubMed/NCBI
|
|
34
|
Hasanein P and Sharifi M: Effects of
rosmarinic acid on acetaminophen-induced hepatotoxicity in male
Wistar rats. Pharm Biol. 55:1809–1816. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bazzi ZA, Lanoue D, El-Youssef M,
Romagnuolo R, Tubman J, Cavallo-Medved D, Porter LA and Boffa MB:
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa)
attenuates breast cancer cell metastatic behaviors through
inhibition of plasminogen activation and extracellular proteolysis.
BMC Cancer. 16:3282016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McMahon B and Kwaan HC: The plasminogen
activator system and cancer. Pathophysiol Haemost Thromb.
36:184–194. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vairaktaris E, Yapijakis C, Nkenke E,
Vassiliou S, Vylliotis A, Nixon AM, Derka S, Ragos V, Spyridonidou
S, Tsigris C, et al: The 1040C/T polymorphism influencing thermal
stability and activity of thrombin activatable fibrinolysis
inhibitor is associated with risk for oral cancer. Am J Hematol.
82:1010–1012. 2007. View Article : Google Scholar : PubMed/NCBI
|
